Mutation

CIViC ID: 336 · Gene: KRAS

Variant Summary

HGVS: —
Variant Type(s): protein_altering_variant
Evidence Items: 45

Evidence Level Distribution

Level A: 2Level B: 26Level C: 1Level D: 15Level E: 1

Evidence Items

Showing CIViC evidence rows where gene = KRAS and variant = Mutation.

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	5
A	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	5
D	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	SCH772984,PI3Kbeta Inhibitor AZD8186	4
B	Predictive	Supports	Resistance	Colorectal Cancer	Chemotherapy,Bevacizumab	4
B	Prognostic	Supports	Poor Outcome	Lung Adenocarcinoma		4
B	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab,Chemotherapy	4
B	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib	4
B	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Selumetinib	4
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Palbociclib,Binimetinib	4
B	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Docetaxel,Erlotinib	4
B	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Docetaxel	4
D	Predictive	Supports	Sensitivity/Response	Cancer	Trametinib	4
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	4
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Trametinib,Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	4
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Selumetinib,Teprotumumab	3
D	Predictive	Supports	Sensitivity/Response	Cancer	G-573,MEK Inhibitor GDC-0623	3
D	Predictive	Supports	Sensitivity/Response	Cancer	AZD5438	3
B	Predictive	Does Not Support	Sensitivity/Response	Lung Adenocarcinoma	Salirasib	3
B	Prognostic	Supports	Poor Outcome	Pseudomyxoma Peritonei		3
D	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	3
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	3
B	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		3
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Abemaciclib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib,Pemetrexed,Docetaxel	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Nivolumab,Atezolizumab	3
B	Predictive	Does Not Support	Sensitivity/Response	Colorectal Cancer	Selumetinib,Cetuximab	3
D	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Decitabine	3
B	Predictive	Supports	Sensitivity/Response	Ovary Serous Adenocarcinoma	Binimetinib	3
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab,Dasatinib	3
B	Predictive	Does Not Support	Resistance	Lung Non-small Cell Carcinoma	MEK Inhibitor RO4987655	3
C	Predictive	Does Not Support	Sensitivity/Response	Colorectal Cancer	Refametinib	2
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib	2
B	Predictive	Supports	Sensitivity/Response	Hepatocellular Carcinoma	Sorafenib,Refametinib	2
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib	2
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Teprotumumab,Erlotinib	2
E	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Immune Checkpoint Inhibitor	2
B	Predictive	Supports	Resistance	Melanoma	Dabrafenib,Vemurafenib	2
B	Predictive	Does Not Support	Sensitivity/Response	Endometrial Cancer	Temsirolimus,Ridaforolimus	2
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib,Afatinib	2
B	Predictive	Does Not Support	Sensitivity/Response	Colorectal Cancer	MEK Inhibitor RO4987655	2
D	Predictive	Supports	Resistance	Colorectal Cancer	Ixazomib	1